BACKGROUND AND PURPOSE: DTI is an MR imaging measure of brain tissue integrity and provides an attractive metric for use in neuroprotection clinical trials. The purpose of our study was to use DTI to evaluate the longitudinal changes in brain tissue integrity in a group of patients with MS. MATERIALS AND METHODS: Twenty-one patients with MS starting natalizumab were imaged serially for 12 months. Gadolinium-enhancing lesions and 20 regions of interest from normal-appearing white and gray matter brain tissue were followed longitudinally. Average values within each region of interest were derived for FA, λ(∥), λ(⊥), and MD. New T1 black holes were identified at 12 months. Analysis was performed by using mixed-model regression analysis with slope (ie, DTI change per month) as the dependent variable. RESULTS: During 1 year, FA increased in gadolinium-enhancing lesions but decreased in NABT (P < .0001 for both). Changes in FA within gadolinium-enhancing lesions were driven by decreased λ(⊥) (P < .001), and within NABT, by decreased λ(∥) (P < .0001). A higher λ(⊥) within gadolinium-enhancing lesions at baseline predicted conversion to T1 black holes at 12 months. MD was unchanged in both gadolinium-enhancing lesions and NABT. CONCLUSIONS: We observed changes in DTI measures during 1 year in both gadolinium-enhancing lesions and NABT. The DTI results may represent possible remyelination within acute lesions and chronic axonal degeneration in NAWM. These results support the use of DTI as a measure of tissue integrity for studies of neuroprotective therapies.
BACKGROUND AND PURPOSE: DTI is an MR imaging measure of brain tissue integrity and provides an attractive metric for use in neuroprotection clinical trials. The purpose of our study was to use DTI to evaluate the longitudinal changes in brain tissue integrity in a group of patients with MS. MATERIALS AND METHODS: Twenty-one patients with MS starting natalizumab were imaged serially for 12 months. Gadolinium-enhancing lesions and 20 regions of interest from normal-appearing white and gray matter brain tissue were followed longitudinally. Average values within each region of interest were derived for FA, λ(∥), λ(⊥), and MD. New T1 black holes were identified at 12 months. Analysis was performed by using mixed-model regression analysis with slope (ie, DTI change per month) as the dependent variable. RESULTS: During 1 year, FA increased in gadolinium-enhancing lesions but decreased in NABT (P < .0001 for both). Changes in FA within gadolinium-enhancing lesions were driven by decreased λ(⊥) (P < .001), and within NABT, by decreased λ(∥) (P < .0001). A higher λ(⊥) within gadolinium-enhancing lesions at baseline predicted conversion to T1 black holes at 12 months. MD was unchanged in both gadolinium-enhancing lesions and NABT. CONCLUSIONS: We observed changes in DTI measures during 1 year in both gadolinium-enhancing lesions and NABT. The DTI results may represent possible remyelination within acute lesions and chronic axonal degeneration in NAWM. These results support the use of DTI as a measure of tissue integrity for studies of neuroprotective therapies.
Authors: M A van Walderveen; W Kamphorst; P Scheltens; J H van Waesberghe; R Ravid; J Valk; C H Polman; F Barkhof Journal: Neurology Date: 1998-05 Impact factor: 9.910
Authors: Sheng-Kwei Song; Jun Yoshino; Tuan Q Le; Shiow-Jiuan Lin; Shu-Wei Sun; Anne H Cross; Regina C Armstrong Journal: Neuroimage Date: 2005-05-15 Impact factor: 6.556
Authors: Rajesh Kumar; Rakesh K Gupta; Virginia Elderkin-Thompson; Amir Huda; James Sayre; Claudia Kirsch; Barry Guze; Steve Han; M Albert Thomas Journal: J Magn Reson Imaging Date: 2008-05 Impact factor: 4.813
Authors: D H Miller; D Soon; K T Fernando; D G MacManus; G J Barker; T A Yousry; E Fisher; P W O'Connor; J T Phillips; C H Polman; L Kappos; M Hutchinson; E Havrdova; F D Lublin; G Giovannoni; A Wajgt; R Rudick; F Lynn; M A Panzara; A W Sandrock Journal: Neurology Date: 2007-04-24 Impact factor: 9.910
Authors: R J Fox; K Sakaie; J-C Lee; J P Debbins; Y Liu; D L Arnold; E R Melhem; C H Smith; M D Philips; M Lowe; E Fisher Journal: AJNR Am J Neuroradiol Date: 2011-12-15 Impact factor: 3.825
Authors: Stuart D Cook; Suhayl Dhib-Jalbut; Peter Dowling; Luca Durelli; Corey Ford; Gavin Giovannoni; June Halper; Colleen Harris; Joseph Herbert; David Li; John A Lincoln; Robert Lisak; Fred D Lublin; Claudia F Lucchinetti; Wayne Moore; Robert T Naismith; Carlos Oehninger; Jack Simon; Maria Pia Sormani Journal: Int J MS Care Date: 2012
Authors: J Hodel; P Besson; O Outteryck; H Zéphir; D Ducreux; A Monnet; D Chéchin; M Zins; M Rodallec; J P Pruvo; P Vermersch; X Leclerc Journal: AJNR Am J Neuroradiol Date: 2012-08-23 Impact factor: 3.825